These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6286554)

  • 1. Clinical trials of WR-2721 with radiation therapy.
    Blumberg AL; Nelson DF; Gramkowski M; Glover D; Glick JH; Yuhas JM; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):561-3. PubMed ID: 6286554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
    Kligerman MM; Blumberg AL; Glick JH; Nelson DF; Glover D; Yuhas JM; Amols HI; Goodman RL
    Cancer Clin Trials; 1981; 4(4):469-74. PubMed ID: 6274534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy.
    Kligerman MM; Turrisi AT; Urtasun RC; Norfleet AL; Phillips TL; Barkley T; Rubin P
    Int J Radiat Oncol Biol Phys; 1988 Jun; 14(6):1119-22. PubMed ID: 2454903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of WR 2721 on radiation response of canine soft tissue sarcomas.
    McChesney SL; Gillette EL; Dewhirst MW; Withrow SJ
    Int J Radiat Oncol Biol Phys; 1986 Nov; 12(11):1957-63. PubMed ID: 3021693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
    Woolley PV; Ayoob MJ; Smith FP; Dritschilo A
    J Clin Oncol; 1983 Mar; 1(3):198-203. PubMed ID: 6321681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WR-2721: a chemotherapy and radiation-protective agent.
    Schein PS
    Cancer Invest; 1990; 8(2):265-6. PubMed ID: 2169331
    [No Abstract]   [Full Text] [Related]  

  • 7. Is the outlook grey for WR-2721 as a clinical radioprotector?
    Denekamp J; Stewart FA; Rojas A
    Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1247-9. PubMed ID: 6307942
    [No Abstract]   [Full Text] [Related]  

  • 8. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid].
    Turrisi AT; Glover DJ; Hurwitz S; Glick J; Norfleet AL; Weiler C; Yuhas JM; Kligerman MM
    Cancer Treat Rep; 1986 Dec; 70(12):1389-93. PubMed ID: 2431774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I controlled trials of WR-2721 and cyclophosphamide.
    Glick JH; Glover D; Weiler C; Norfleet L; Yuhas J; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1777-80. PubMed ID: 6090370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction.
    McDonald S; Meyerowitz C; Smudzin T; Rubin P
    Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):747-54. PubMed ID: 8040020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trials of WR-2721 and cis-platinum.
    Glover D; Glick JH; Weiler C; Yuhas J; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1781-4. PubMed ID: 6090371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy.
    Glover D; Fox KR; Weiler C; Kligerman MM; Turrisi A; Glick JH
    Pharmacol Ther; 1988; 39(1-3):3-7. PubMed ID: 2849130
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxicity of WR-2721 administered in single and multiple doses.
    Kligerman MM; Glover DJ; Turrisi AT; Norfleet AL; Yuhas JM; Coia LR; Simone C; Glick JH; Goodman RL
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1773-6. PubMed ID: 6090369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of cultured mammalian cells by S-2-(3-aminopropylamino)ethylphosphorothioic acid(WR-2721).
    Antoku S
    Int J Radiat Oncol Biol Phys; 1983 Oct; 9(10):1481-5. PubMed ID: 6313559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
    Glover D; Glick JH; Weiler C; Hurowitz S; Kligerman MM
    J Clin Oncol; 1986 Apr; 4(4):584-8. PubMed ID: 3007686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II trials of WR-2721 and cis-platinum.
    Glover D; Glick JH; Weiler C; Fox K; Turrisi A; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1509-12. PubMed ID: 3019969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies.
    Coia L; Krigel R; Hanks G; Comis R; Algazy K; Peters R; McCulloch W; Schien P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):791-4. PubMed ID: 1312076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection by WR-2721 of human bone marrow function following irradiation.
    Constine LS; Zagars G; Rubin P; Kligerman M
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1505-8. PubMed ID: 2428794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution.
    Rasey JS; Nelson NJ; Mahler P; Anderson K; Krohn KA; Menard T
    Radiat Res; 1984 Mar; 97(3):598-607. PubMed ID: 6328565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for initial clinical trials and future development of radioprotectors.
    Phillips TL
    Cancer Clin Trials; 1980; 3(2):165-73. PubMed ID: 6253097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.